Clinical Trial Protocol
Iranian Registry of Clinical Trials

01 Nov 2026

A study to compare the relative bioavailability of Jaber and Lundbeck companies of escitalopram 20 mg tablets formulations in 24 healthy adult volunteers under fasting conditions

Protocol summary

Study aim

The study aims to evaluate the bioequivalence of escitalopram 20 mg tablets produced by two different pharmaceutical companies under fasting conditions

Design

This randomized, single-dose, two-way, crossover study is conducted to compare the pharmacokinetic of escitalopram and Cipralex® tablets in 24 healthy adults volunteers. Volunteers will be sorted and receive a number from 1 to 24. In the first phase of the study, 12 volunteers will receive escitalopram manufactured by Jaber and the remaining 12 volunteers will receive Cipralex® produced by Lundbeck company. The administered drugs will be replaced by each other in the second phase of the study.

Settings and conduct

The dose administration and subsequent sample collection will be performed in S. Motahhari hospital (Gonbade Kavous, Iran).

Participants/Inclusion and exclusion criteria

Inclusion criteria:18-55 years of age. The subject is available for the entire study period and is willing to adhere to protocol requirements as evidenced by written informed consent. Good health at screening. Exclusion criteria: History of any drug hypersensitivity or intolerance. Significant history or current evidence of chronic disease. Receipt of any drug as part of a research study within 30 days prior to the present study.

Intervention groups

First intervention group: A single 20 mg oral dose of escitalopram (1 tablet) manufactured by Jaber company to 12 subjects. Second intervention group: A single 20 mg oral dose of Cipralex (1 tablet) manufactured by Lundbeck company to 12 subjects. Since in this study, the volunteers will receive both Test and Reference drugs, each volunteer will act as his own control.

Main outcome variables

Drug plasma concentration; Area under the plasma concentration-time curve

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20130626013776N38**
Registration date: **2021-04-23, 1400/02/03**
Registration timing: **prospective**

Last update: **2021-04-23, 1400/02/03**
Update count: **0**

Registration date

2021-04-23, 1400/02/03

Registrant information

Name
Hossein Amini
Name of organization / entity
Golestan University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 17 1442 1651
Email address
hamini@sbmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-05-21, 1400/02/31

Expected recruitment end date

2022-02-20, 1400/12/01

Actual recruitment start date

empty

Actual recruitment end date
empty
Trial completion date
empty

Scientific title
A study to compare the relative bioavailability of Jaber and Lundbeck companies of escitalopram 20 mg tablets formulations in 24 healthy adult volunteers under fasting conditions

Public title
Bioequivalence study of escitalopram 20 mg tablets
Purpose
Basic scienece
Inclusion/Exclusion criteria
Inclusion criteria:
18-55 years of age The subject is able and willing to provide signed informed consent. The subject is available for the entire study period and is willing to adhere to protocol requirements as evidenced by written informed consent. The subject has stable residence and telephone. Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.
Exclusion criteria:
History of allergy or sensitivity to escitalopram. History of any drug hypersensitivity or intolerance which, in the opinion of the investigator,would compromise the safety of the subject of the study. Significant history or current evidence of chronic infectious disease, system disorder or organ dysfunction. Presence of gastrointestinal disease or history of malabsorption within the last year. History of a medical disorders occurring within the last year that required hospitalization or medication. Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to dosing. Receipt of any drug as part of a research study within 30 days prior to the present study. Donation or significant loss of whole blood (480 ml or more) within 30 days prior to the present study.
Age
From **18 years** old to **55 years** old
Gender
Both

Phase
Bioequivalence
Groups that have been masked
No information
Sample size
Target sample size: **24**
More than 1 sample in each individual
Number of samples in each individual: **13**
A volume of 3 ml of blood is obtained in each sampling time through a venous cannula
Randomization (investigator's opinion)
Randomized
Randomization description
Each subject is identified by a number from 1 to 24. This number is allocated according to their entrance to volunteers' list in the screening day. Then, the following randomization table is used according to the crossover design of the study. All participants randomized into two sequences of Test/Reference and Reference/Test products
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Crossover
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Golestan University of Medical Sciences
Street address
Falsafi Building, Sari Road Km 5
City
Gorgan
Province
Golestan
Postal code
4934174515
Approval date
2021-02-21, 1399/12/03
Ethics committee reference number
IR.GOUMS.REC.1400.003

Health conditions studied

1

Description of health condition studied
.
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Drug plasma concentration
Timepoint
At time zero and 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 24, 48 and 96 h after drug administration
Method of measurement
Blood sampling and measurement of drug concentrations by high-performance liquid chromatography

2

Description

Area under plasma concentration-time curve

Timepoint

At time zero and 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 24, 48 and 96 h after drug administration

Method of measurement

Blood sampling and measurement of drug concentrations by high-performance liquid chromatography

Secondary outcomes

1

Description

Plasma half-life

Timepoint

From the terminal 86 hours of plasma concentration-time profile

Method of measurement

Blood sampling and drug analysis by high-performance liquid chromatography method

Intervention groups

1

Description

Intervention group: Oral administration of a single 20 mg dose of escitalopram (1 tablet) manufactured by Jaber to healthy volunteers under fasting condition in the morning of the experiment day

Category

Treatment - Drugs

2

Description

Intervention group: Oral administration of a single 20 mg dose of Cipralex (1 tablet) manufactured by Lundbeck to healthy volunteers under fasting condition in the morning of the experiment day

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Dialysis Center, S. Motahhari Hospital

Full name of responsible person

Yahya Naserifard

Street address

Taleghani Street

City

Gonbade Kavous

Province

Golestan

Postal code

4916817693

Phone

+98 17 3252 5972

Fax

+98 17 3252 5972

Email

haminhplc@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Jaber Pharmaceuticals

Full name of responsible person

Mehdi Bakhshayesh

Street address

Km 4 Karaj road

City

Tehran

Province

Tehran

Postal code

13185-1739

Phone

+98 21 4450 3323

Fax

+98 21 4450 3530

Email

headoffice@jaber-pharma.com

Web page address

http://jaber-pharma.com/home

Grant name

Bioequivalence Study of escitalopram

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Jaber Pharmaceuticals

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Industry

Person responsible for general inquiries

Contact

Name of organization / entity

Gorgan University of Medical Sciences

Full name of responsible person

Hossein Amini

Position

Associate professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy
Street address
Sari Road, Km 2
City
Gorgan
Province
Golestan
Postal code
4934174515
Phone
+98 17 3252 5972
Fax
+98 17 3252 5972
Email
haminhplc@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Gorgan University of Medical Sciences
Full name of responsible person
Hossein Amini
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Sari Road, Km 2
City
Gorgan
Province
Golestan
Postal code
4934174515
Phone
+98 17 3252 5972
Fax
+98 17 3252 5972
Email
haminhplc@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Gorgan University of Medical Sciences
Full name of responsible person
Hossein Amini
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Sari Road, Km 2
City
Gorgan
Province
Golestan
Postal code
4934174515
Phone
+98 17 3252 5972
Fax
+98 17 3252 5972
Email
haminhplc@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD
Data are confidential and need permission from the company.
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available